Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

VGI: Moving Beyond Bt15bn Worth of Thai OOH Ads Market

BTS: City Solutions Provider Set to Expand Business Frontier

EASTW: Surging Electricity Cost Pressured Margin at Least Until 4Q19

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

<p>VGI's main shareholder BTS is selling USD 129 million worth of shares post market close today. In this insight, we will provide quick thoughts on the deal. We think the large deal size relative to its liquidity is not an issue as evidenced by past deal. </p>

VGI's main shareholder BTS is selling USD 129 million worth of shares post market close today. In this insight, we will provide quick thoughts on the deal. We think the large deal size relative to its liquidity is not an issue as evidenced by past deal. 

VGIグローバルメディアプレースメント：過去の取引から高い収益を上げ、独占的に高成長を実現

VGI PCL

VGIグローバルメディアプレースメント：過去の取引から高い収益を上げ、独占的に高成長を実現